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Background: Treatment of cystic ﬁbrosis (CF) patients with inhaled hypertonic saline (HS) solutions is safe, beneﬁcial and reduces exacerbation
rates. We studied contamination of solutions used by Israeli CF patients for prolonged periods.
Methods: The study addressed whether daily opening of previously unopened solutions caused contamination, survival of 6 CF-associated bacteria
in artiﬁcially inoculated solutions, in-use contamination of solutions and patterns of their use by patients.
Results: Repeated opening did not contaminate solutions and survival of indicator bacteria was variable.Mycobacterium abscessus survived in 3%
HS solution for 6 weeks and Burkholderia cenocepacia and Pseudomonas aeruginosa were longer. In 30/76 (39.5%) of used solutions 49
contaminants were found, none being common CF-associated pathogens.
Conclusions: Most CF-related bacteria survived to some degree in HS. Approximately 40% of solutions used by patients were contaminated by
organisms of uncertain signiﬁcance. Our ﬁndings highlight the potential risk posed by contamination of HS solutions and support recommendations to
use sterile unit-dose formulations.
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Cystic fibrosis (CF) is caused by mutations in the CFTR
gene that result in the absence or dysfunction of the protein that
regulates ion transport across the apical membrane at the
surface of certain epithelia. In the lungs, CFTR dysfunction
leads to airway surface liquid (ASL) depletion and thickened
and viscous mucus that adhere to airway surfaces [1]. The result
is decreased mucociliary clearance (MCC) and impaired host
defenses. Dehydrated, thickened secretions lead to endobronchial
infection with a limited spectrum of distinctive bacteria mainly
Staphylococcus aureus and Pseudomonas aeruginosa, and anby Elsevier B.V. All rights reserved.
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of bronchiectasis and progressive obstructive airways disease.
Pulmonary insufficiency is responsible for most CF-related deaths
[2,3].
Inhaled hyperosmolar agents such as hypertonic saline induce
osmotic flow of water into the mucus layer, thereby rehydrating
secretions and improving mucus rheology and transportability of
sputum [4,5], and increased hydration of the airway surface [6,7].
Inhalations of hypertonic saline (4 ml BID following pretreat-
ment with bronchodilators) improved MCC and lung function
and reduced exacerbation rate in patients with CF [8–11]. This
improvement in mucociliary function may reduce bacterial load
and chronic inflammation within the airways with a concomitant
stabilization of lung function. Hypertonic saline is inexpensive,
safe, and well tolerated in young children [10].
Since HS inhalation has become an acceptable treatment for
CF patients, Israeli CF patients have been using it in increasing
numbers as long term therapy within the home setting. However,
until very recently in Israel, as inmany other countries, there were
no standardized sterile unit-dose HS formulations. Compounding
pharmacies produce large-volume bottled solutions of HS, which
patients use for prolonged periods. Furthermore, some patients
prepare the HS solution at home by diluting sterile solutions
containing higher concentrations of sodium chloride (14.6%
and above) with water for injection or normal saline (0.9%) to
achieve the desired concentration for inhalations (3–7%). These
solutions are used by patients, often for weeks, under non-sterile
conditions, with no consideration of the potential for contamina-
tion [12–14]. Therefore, concerns regarding the acquisition of
potential pathogens by patients with CF through repeated use
of pre-prepared HS solutions for inhalations were raised.
Based upon prevention as a primary goal for infection control
in CF, it is self-evident that any inhaled medication treating
CF patients should be sterile. Therefore, the potential for
contamination of different HS solutions in use at CF clinics
and patients' homes was considered worthy of scrutiny.
The purpose of this study was to investigate bacterial con-
tamination of hypertonic saline solutions under the following
circumstances:
1) The effect of simple daily opening and closing of previously
unopened hypertonic saline solutions at various concentrationsTable 1
Distribution of 76 HS solutions submitted by 43 patients.
Number of HS solutions per patient Number of patients Nu
so
0
1 28 b 13
2 7
3 5
4 1
7 1
8 1
Total 43 1
a Number of patients × number of solutions tested.
b 2 solutions were obtained from CF outpatient clinics.(3%, 7%, 14.6%) under clean conditions and at defined
intervals over a one month period.
2) Survival of selected CF-associated bacteria in artificially
inoculated hypertonic saline solutions.
3) In-use contamination of hypertonic saline solutions in different
settings (out-patient clinics, patients' homes).
4) An additional objective was to document the manner of
use of these solutions in the home and clinic settings, in
order to identify handling habits that might affect bacterial
contamination.2. Settings
2.1. CF outpatient clinics at three large hospitals
Patients were asked to bring HS solutions they used at home,
and were almost finished, for submission to the laboratory. Some
patients brought their solutions at several visits (Table 1). The
questionnaire was completed once for each patient at a clinic
visit. Inhalations were routinely performed at the clinics by CF
nurses using the clinics' nebulizers and HS solutions. Each
patient was given a decontaminated nebulizer with new solutions
for these treatments. There was no standard type of nebulizer in
use by all clinics and patients.2.2. Clinical microbiology laboratory
Laboratory experiments and cultures of solutions in use were
performed at the Hadassah-Hebrew University Medical Centre
clinical microbiology laboratory.3. Methods
The institutional review boards of the Hadassah-Hebrew
University Medical Center at Mt. Scopus and the Schneider
Children's Medical Center in Petah Tikva approved the protocol
with verbal informed consent of the patients or their parents. At
the Chaim Sheba Medical Center at Tel Hashomer, written
informed consent was required.mber of contaminated HS
lutions per patient
Total HS solutions a
1 2 4
b 15 28
2 4 1 14
2 3 15
1 4
1 7
1 8
8 23 1 1 76
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The following HS solutions available in Israel were studied: 3%
sodium chloride 500 ml and 7% sodium chloride 160 ml, both
from compounding pharmacy A; 7% sodium chloride 100 ml
from compounding pharmacy B; 7% sodium chloride 100 ml from
compounding pharmacy C; and a commercial preparation of
14.6% sodium chloride for injection, USP, 40 ml. All solutions
were labeled as sterile.
The study was divided into 4 parts:
Part 1: The effect of daily opening and closing of containers
on the contamination of previously unopened HS solutions
was investigated. The purpose of this was to provide a
comparator for “real world” use in clinics or by patients in
their homes.
Triplicates of each HS solution were opened and closed
aseptically once a day for 1 month inside a class IIA biological
safety cabinet using ungloved hands after disinfection with
an alcohol based hand sanitizer. The rubber diaphragm and
closure of each container were disinfected with 70% ethanol
before opening. Volumes of 0.4–2 ml of each solution were
drawn daily according to the capacity of each container,
simulating real-life practice. Larger volumes of 4–50 ml,
depending on container capacity, were collected at first
opening (baseline), 24 h, 72 h, 7 d, 14 d and 30 d. Quantitative
bacterial cultures were set up for each specimen.
In anticipation of low bacterial densities in this part of
the study, quantitative cultures were performed using a
membrane filtration method (Millipore Microfil®, Millitech,
Israel). Samples were drawn through sterile 0.45 μm pore
diameter membranes. All procedures were carried out
according to the manufacturer's instructions in a class IIA
biological safety cabinet. Filters were aseptically transferred to
tryptic soy agar (TSA, Novamed, Jerusalem, Israel) and
incubated in air at 35 ºC for 48 h and subsequently at room
temperature for 5 more days. Any organisms grown were
identified by routine clinical laboratory methods. All laboratory
tests were conducted at the Clinical Microbiology Unit at the
Hadassah-Hebrew University Medical Center.
Part 2: Survival of well recognized CF-associated bacteria in
the HS solutions mentioned above was tested for the following
species:
1) Staphylococcus aureus (ATCC 25923)
2) Pseudomonas aeruginosa (ATCC 27853)
3) Haemophilus influenzae (ATCC 49247)
4) Stenotrophomonas maltophilia (clinical isolate from a
non-CF patient)
5) Burkholderia cenocepacia (clinical isolate from CF
patient)
6) Mycobacterium abscessus (clinical isolate from CF
patient)
Saline suspensions of 0.5 McFarland turbidity standard
of each bacterium were introduced, at initial opening, into
6 replicates of each type of HS solution to generate a
concentration of approximately 7.5 × 105 CFU/ml in each
bottle. Viable counts of the inocula (baseline) and the bacterialdensity in each bottle were performed by the drop-plate method
[15]. H. influenzae and M. abscessus were enumerated on
chocolate agar and Middlebrook agar respectively (Novamed,
Jerusalem, Israel). The other species were cultured on TSA.
Viable counts were performed at deﬁned time intervals: 24 h,
72 h, 7 d, 14 d, 30 d and 42 d.
Part 3: Seventy-six unselected samples of HS solutions from
CF patients, including two from outpatient clinics, were
collected anonymously, close to their final use. For each,
the entire remaining solution was drawn aseptically, and
cultures were performed by the membrane filtration method as
described above. Equal parts of each sample were filtered
aseptically on separate membranes for culture on both TSA
and Middlebrook agar. TSA plates were incubated in air
at 35 °C for two days and 6 days for Middlebrook agar
plates. The identification of any bacterial or fungal growth,
irrespective of quantities, was carried out by routine clinical
laboratory methods.
In addition to the characteristics of the formulation tested, the
following data were recorded for each sample: the patient's
clinic, ethnic group, use of refrigeration and time interval from
last use to processing at the laboratory.
Part 4: In order to identify factors that might influence
the sterility of the solutions, a questionnaire on the home
use of HS solutions was filled out anonymously by patients
from the different clinics. Issues examined included storage
of the containers, duration of usage of each, frequency
and duration of exposure of a solution to open air, method
used for obtaining HS solution from containers, the use
of a syringe and frequency of its exchange if this method
was used.
It should be noted that since the questionnaires were gathered
anonymously, contamination results could not be associated with
usage conditions by specific patients.
Statistical methods: associations between contaminants and
handling of the solutions by patients and clinics were evaluated
using the chi-square test and Fisher's exact test.
4. Results
Part 1: HS solutions did not become contaminated after one
month of repeated opening in the laboratory environment.
This supported the assumption that with good aseptic practice,
opening and closing the containers for a month were not
associated with detection of contaminants in the solutions.
Part 2: Survival of the bacteria in the different solutions was
variable (Fig. 1). H. influenzae did not survive in any HS
solution. Most organisms survived better in the 3% and the
14.6% solutions than the 7% solutions. Some survived in
the 3% HS solution for 6 weeks (M. abscessus) or longer
(B. cenocepacia and P. aeruginosa).
Part 3: Out of 76 solutions from 41 CF patients (Table 1)
and two CF outpatient clinics, 30 (39.5%) were contam-
inated with 49 organisms, with a mean of 1.6 organisms
per sample (Table 2). Various contaminants were found:
67.3% gram-positive bacteria, 22.4% gram-negative bacteria
Fig. 1. Survival of six cystic fibrosis associated organisms over six weeks in different hypertonic saline formulations shown as % concentrations. A, B and C represent
different manufacturers.
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tioned above were isolated from any contaminated fluid. The
two solutions from outpatient clinics yielded no growth.
No statistically significant associations were found between
contaminants and handling of the solutions by patients, clinic,
type of solution, refrigeration, time elapsed since last use,
frequency of needle and syringe change or ethnicity.
Part 4: The questionnaire regarding the use of the HS
solutions was completed by 91 patients. Forty-six (51.1%)
were male with a mean age of 17.7 ± 12.2 (mean ± SD).
Fifty-nine (64.8%) were from the Hadassah-Hebrew Uni-
versity Medical Center at Mt. Scopus, 24 (26.4%) were from
the Schneider Children's Medical Center in Petah Tikva and
8 (8.8%) were from the Chaim Sheba Medical Center at Tel
Hashomer.
Forty-five patients (49.5%) used solutions in a simple plastic
bottle with a screw-cap closure, while 46 (50.5%) used containers
with a rubber diaphragm. Normal use of containers with a
screw-cap closure offers many opportunities for contamination:
3/45 respondents (6.7%) reported that the solutions remained
open to air for 10 min or more during each use. Withdrawal of
solution using a syringe and needle after opening the cap wasreported by 19/45 respondents (42.2%); 11/45 respondents
(24.4%) pierced the plastic with the needle to withdraw the
solution; 11/45 respondents (24.4%) simply poured the estimated
volume needed after opening the bottle normally and 4/45 res-
pondents (8.9%) used other means.
The major inappropriate practices in handling the HS so-
lutions are summarized in Table 3. Only 24 (26.4%) of the 91
respondents refrigerated their solutions between uses. Thirty
(33.0%) respondents used their solutions for more than 1 month,
24 (26.4%) for 1 month, 15 (16.5%) for 3 weeks and 22 (24.2%)
for 2 weeks. Needles were changed monthly or less frequently by
43 respondents (47.8%).
Ninety respondents answered the question regarding syringes
and needles. Six (6.7%) changed their equipment after each use; 3
(3.3%) after a day or two and 27 (30.0%) once every week or two.
Eleven (12.2%) didn't use syringe and needle at all and simply
poured the estimated volume needed after opening the plastic
bottle with a screw-cap closure as described above.5. Discussion and conclusions
The issue of the survival of CF-associated bacteria in HS
solutions has not been addressed before in a systematic way.
Table 2
Distribution of the organisms found in hypertonic saline solutions.
Organism Total (%)
Gram-positive bacteria
Bacillus sp. 12 (24.5%)
Micrococci 9 (18.4%)
Diphtheroids 7 (14.3%)
Coagulase negative staphylococcus 4 (8.2%)
Rhodococcus sp. 1 (2%)
Total gram-positive 33 (67.3%)
Gram-negative bacteria
Enterobacter cloacae 3 (6.1%)
Pseudomonas spp. (non-P. aeruginosa) 3 (6.1%)
Myroides odoratum 1 (2%)
Escherichia coli 1 (2%)
Acinetobacter lwoffii 1 (2%)
Klebsiella oxytoca 1 (2%)
Klebsiella pneumoniae 1 (2%)
Total gram-negative 11 (22.4%)
Fungi
Aspergillus niger 2 (4.1%)
Candida parapsilosis 1 (2%)
Acremonium kiliense 1 (2%)
Curvularia sp. 1 (2%)
Total fungi 5 (10.2%)
Total organisms 49 (100%)
Total positive samples 30
Mean organisms per sample 1.6
Total cultured solutions 76
% contaminated solutions 39.5
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to many classical CF-associated species. While H. influenzae
unsurprisingly did not survive for any length of time, most of the
others survived from days to weeks in some of the formulations.
The survival for at least 6 weeks in 3% HS by M. abscessus,
B. cenocepacia and P. aeruginosa was particularly worrisome.
The possible reasons for the better survival of most organisms in
the 3% and the 14.6% solutions than the 7% solutions were
beyond the scope of this study.
These findings emphasize the concern that aerosolized
solutions, initially contaminated by contact with respiratory
secretions or insufficient hand hygiene or poor handling during
use, may be reservoirs for the transmission of infectious organisms
to this vulnerable group of patients.
In-use contamination was found in about 40% of containers
examined. No statistically significant association was found
between this contamination of HS solutions and their character-
istics and handling issues. However, it should be noted that none
of classical bacterial hazards for CF patients, as included in Part 2
of this study, were found as contaminants. Nevertheless, it shouldTable 3
Summary of the main problematic practices in patients' use of HS solutions in
their homes, n = 91.
Description No. of patients %
HS solution not refrigerated 67 74
Prolonged use (1 month or longer) 54 59
Same syringe used for 1 month or longer 43 48be noted that three non-fermentative gram-negative rods were not
fully identified and may potentially include taxa associated in
recent years with CF. Molecular studies have indicated that many
previously unrecognized bacteria are likely common inhabitants
of the airways in CF [16]. The presence of some filamentous
fungi also deserves comment. The organisms found were very
varied and the number of samples examined was very limited, so
associations between some of the variables studied may not have
been evident.
Our study has several limitations that should be considered.
One is that more than one solution was collected from some of the
patients. While this raises some questions as to the interpretation of
the contamination data, especially in view of the difficulty in
relating individual patients and their contamination results to their
particular usage habits, it is still noteworthy that almost 40% of the
solutions were contaminated. Another potential limitation is the
use of simple aerobic bacterial and fungal cultures of planktonic
organisms in a field in which much weight is given to biofilms and
their associated microbiota. In looking at contamination of inhaled
nebulized solutions we were primarily interested in organisms in
suspension that might be incorporated in the droplets during the
nebulization process. Specific evaluation of possible biofilm
formation and microbiology in HS containers was not feasible in
the framework of this study, so this question remains unanswered
at present.
We did not specifically assess patient education by health care
providers such as primary care physicians, nurses and pharmacists,
as to the correct usage of HS solutions. Education for infection
control is a standard practice at the participating CF clinics. The
types of contaminations demonstrated in this study (Table 2) and
the main inappropriate handling practices for HS solutions in the
domestic environment (Table 3) are almost certainly preventable
by simple interventions such as adequate education of the patients
and their families, coupled with use of unit-dose containers for
these HS solutions.
Single unit-dosemedication vials are always preferred [17]. The
microbial contamination of home and hospital nebulizers in CF
patients has been assessed [18,19], as well as patients' hands and
clinic environment [20]. O'Malley (2007) concluded that there is a
low risk of growth of P. aeruginosa, S. aureus or H. influenzae in
small volume nebulizer medication cups over a 24-hour period,
which supports the practice of replacing the nebulizer every 24 h
rather than cleaning or disinfecting it between uses [18]. Blau et al.
(2007) demonstrated that a majority of nebulizers used at home
by CF patient are contaminated, particularly when patients do not
recall cleaning instructions, and that pseudomonas constituted
the major contaminant [19]. Clinically, this might be particularly
important during the initial stages of intermittent airway infection
withP. aeruginosa. A continuous cycle of reinfectionmay occur in
these patients, where contaminated secretions are transmitted by
contact to nebulizer equipment, and later are inhaled back into the
airways, generally increasing the risk of permanent infection with
concomitant poor prognosis [21].
In a review on the organisms causing chronic airway
infections in the CF patient population, Gilligan noted that
enteric bacilli and gram-negative glucose-non-fermenting
bacilli other than P. aeruginosa and Pseudomonas cepacia
555O. Peled et al. / Journal of Cystic Fibrosis 13 (2014) 550–556(Burkholderia cenocepacia and related species) are occa-
sionally recovered from the respiratory secretions of CF
patients [22]. None of these organisms seemed to persist
for extended periods. Any role that they may have in lung
disease of these patients is likely to be secondary to that of
the organisms mentioned previously. Organisms represented
in that review included Enterobacter cloacae (6.1% of our
contaminants, Table 1), Escherichia coli, Acinetobacter
lwoffii, Klebsiella oxytoca and Klebsiella pneumoniae (each
comprising 2% of our contaminants).
A report by Klinger et al. on the occurrence and antimicrobial
susceptibility of gram-negative non-fermentative bacilli in CF
patients concluded that the frequency of organisms other than
P. aeruginosa in respiratory tract cultures from CF patients has
increased [23].
In recent years, much attention has been paid to a range of
additional organisms, especially glucose non-fermenting gram-
negative rods, which are increasingly being encountered in CF
sputum [24]. This should be seen in the context of the growing
evidence that suggests that pulmonary infections in CF should
be considered from a microbial community perspective, since
CF airways contain highly complex, polymicrobial bacterial
communities. The notion that has held sway until now, that a
limited number of microorganisms contribute to the disease
state, may well be an oversimplification [25–27].
Undoubtedly, modern genetic and bioinformatics methods
will dramatically expand our knowledge of the microbiome in
CF airways and inform radical changes in the prevention and
treatment of CF lung disease in the next few years.
Regarding fungi, Nagano et al. reported that Acremonium spp.
are found relatively infrequently in CF sputum, and that their
clinical significance is unknown [28]. Infection and allergic
bronchopulmonary aspergillosis (ABPA) due to Aspergillus
fumigatus have been associated with deterioration in CF [29].
We encountered Aspergillus niger among the contaminants of
the hypertonic saline solutions. The only reported case of
presumed severe A. niger infection in CF was found in a study
by Quattrucci et al. who evaluated complications and survival
after sequential bilateral lung transplantation in patients with
end-stage cystic fibrosis [30].
While we acknowledge that the possible role of the organisms
found in the solutions in our study is unclear, the contamination
of multi-dose HS solutions used for inhalation demonstrated in
our study is unacceptable in respiratory therapy. Therefore, HS
solutions should be restricted to unit-dose vials only.
Our findings were presented at various forums and subsequent-
ly, in January 2012, commercially compounded, sterile unit dose
vials for CF patients were made available for the first time in Israel.
The product contains 6% NaCl and has been added to the list of
medications subsidized by the government of Israel.
The interesting behaviors revealed in the questionnaire,
together with our contamination findings suggest that more
attention should be paid to instruction of patients and their
families regarding the safe use of materials introduced into
the compromised airways of CF patients [31]. Manufacturers
should also ensure that their products encourage safe use by
adhering to the recommendation for sterile unit-dose vials.Funding
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